| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
7,479 |
5,227 |
$353K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
595 |
485 |
$34K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
572 |
468 |
$26K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
1,283 |
959 |
$9K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
272 |
216 |
$6K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
1,037 |
762 |
$6K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
87 |
68 |
$4K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
603 |
242 |
$4K |
| J2010 |
Injection, lincomycin hcl, up to 300 mg |
146 |
118 |
$1K |
| 81003 |
|
928 |
698 |
$758.73 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
578 |
459 |
$327.92 |
| 82947 |
|
178 |
133 |
$202.10 |
| 82043 |
|
30 |
24 |
$60.84 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
16 |
15 |
$21.10 |
| 82570 |
|
16 |
12 |
$20.95 |
| 3008F |
|
2,460 |
1,727 |
$0.00 |
| 1034F |
|
235 |
157 |
$0.00 |
| 1036F |
|
413 |
313 |
$0.00 |
| 3079F |
|
252 |
200 |
$0.00 |
| 1125F |
|
1,361 |
1,053 |
$0.00 |
| 3074F |
|
543 |
393 |
$0.00 |
| 1126F |
|
858 |
636 |
$0.00 |
| 3080F |
|
12 |
12 |
$0.00 |
| 3078F |
|
315 |
171 |
$0.00 |
| 1159F |
|
2,569 |
1,705 |
$0.00 |
| 1160F |
|
2,559 |
1,702 |
$0.00 |
| 3077F |
|
37 |
27 |
$0.00 |